Takeda added some more firepower to the company’s immuno-oncology game on January 10 when the Japanese giant announced it will exercise an option to acquire U.K.-based Adaptate Biotherapeutics.
Mergers and acquisitions are part of the lifeblood of the pharmaceutical industry, as companies flex their pocketbooks to acquire pipelines and talent to bolster and complement their own programs. While there were significant moves during the past 12 months, 2021 was largely quieter than previous years.
Novartis is expanding the company’s position in gene therapy and retinal diseases with the $1.5 billion acquisition of UK-based ocular gene therapy company Gyroscope Therapeutics.
Paris-based Sanofi is buying South San Francisco’s Amunix Pharmaceuticals in a deal topping $1.225 billion.
© Vifor Pharma.CSL announced on December 14 that the company has begun the process to acquire Vifor Pharma, putting an end to rumors that had been escalating since the beginning of December.
Fingerpaint, biopharma’s global commercialization partner for analytics-enabled integrated solutions, announced the acquisition of MedThink, a North Carolina–based company that empowers healthcare providers through medical communications.
Less than three months after Swedish Orphan Biovitrum AB (Sobi) agreed to be acquired by Advent International and GIC Special Investments for nearly $8 billion, the deal fell through after AstraZeneca withheld the company’s 8 percent stake from the buyout offer.
Sanofi is expanding the company’s research into skin therapies after agreeing to acquire the Australian firm Origimm Biotechnology, which specializes in treatments for various types of skin diseases.
Shares of Dicerna Pharmaceuticals exploded today after Novo Nordisk announced plans to acquire the Lexington, Mass.-based , a company developing RNAi therapeutics, company for $3.3 billion.
Kala Pharmaceuticals Inc., a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, announced the acquisition of Combangio Inc., a private, clinical-stage company developing regenerative biotherapies for severe ocular surface diseases.
